Evidence map›Paper›PMID 31781669›Full record

ArticleJournal of diabetes research2019

A Novel Liposome Formulation Carrying Both an Insulin Peptide and a Ligand for Invariant Natural Killer T Cells Induces Accumulation of Regulatory T Cells to Islets in Nonobese Diabetic Mice.

Hidetoshi Akimoto, Emi Fukuda-Kawaguchi, Omar Duramad, Yasuyuki Ishii, Kazunari Tanabe

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of diabetes research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Hidetoshi AkimotoResearch Division, REGiMMUNE Corporation, 35-3 Nihonbashi Hakozaki-cho, BRICK GATE 5F, Chuou-Ku, Tokyo 103-0015, Japan.ORCID https://orcid.org/0000-0003-3486-1602
Emi Fukuda-KawaguchiResearch Division, REGiMMUNE Corporation, 35-3 Nihonbashi Hakozaki-cho, BRICK GATE 5F, Chuou-Ku, Tokyo 103-0015, Japan.ORCID https://orcid.org/0000-0003-2578-7789
Omar DuramadResearch Division, REGiMMUNE Inc, 820 Heinz Ave, Berkeley, CA 94710, USA.ORCID https://orcid.org/0000-0003-4417-7230
Yasuyuki IshiiResearch Division, REGiMMUNE Corporation, 35-3 Nihonbashi Hakozaki-cho, BRICK GATE 5F, Chuou-Ku, Tokyo 103-0015, Japan.ORCID https://orcid.org/0000-0002-9973-6469
Kazunari TanabeDepartment of Urology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-Ku, Tokyo 162-8666, Japan.
Tokyo Women's Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Type 1 diabetes (T1D) is an autoimmune disease caused by the destruction of pancreatic

Indexed as

Adoptive TransferAnimalsDiabetes Mellitus, Type 1Disease Models, AnimalDrug CompoundingFemaleForkhead Transcription FactorsGalactosylceramidesHypoglycemic AgentsInsulinIslets of LangerhansLiposomesMice, Inbred NODMice, SCIDNatural Killer T-CellsPeptide Fragmentsalpha-galactosylceramideForkhead Transcription FactorsFoxp3 protein, mouseGalactosylceramidesHypoglycemic AgentsInsulinLiposomesPeptide Fragments

Identifiers

PMID31781669
PMCPMC6855036
OpenAlexW2981345646

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.